Use of Immunosuppression and the Risk of Subsequent Overall or Cancer Mortality.
Kempen JH, Newcomb CW, Washington TL, Foster CS, Sobrin L, Thorne JE, Jabs DA, Suhler EB, Rosenbaum JT, Sen HN, Levy-Clarke GA, Nussenblatt RB, Bhatt NP, Lowder CY, Goldstein DA, Leiderman YI, Acharya NR, Holland GN, Read RW, Dunn JP, Dreger KA, Artornsombudh P, Begum HA, Fitzgerald TD, Kothari S, Payal AR, Daniel E, Gangaputra SS, Kaçmaz RO, Liesegang TL, Pujari SS, Khachatryan N, Maghsoudlou A, Suga HK, Pak CM, Helzlsouer KJ, Buchanich JM; Systemic Immunosuppressive Therapy for Eye Diseases Cohort Study Research Group.
Kempen JH, et al. Among authors: suhler eb.
Ophthalmology. 2023 Dec;130(12):1258-1268. doi: 10.1016/j.ophtha.2023.07.023. Epub 2023 Jul 26.
Ophthalmology. 2023.
PMID: 37499954